Objective We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D). Research Design and Methods 732 recently diagnosed T2D patients from the IMI-DIRECT study were extensively phenotyped over three years, including measures of insulin sensitivity (OGIS), β-cell glucose sensitivity (GS) and insulin clearance (CLIm) from mixed meal tests, liver enzymes, lipid profiles, and baseline regional fat from MRI. The associations between the longitudinal metabolic patterns and HbA1c deterioration, adjusted for changes in BMI and in diabetes medications, were assessed via stepwise multivariable linear and logistic regression. Results Faster HbA1c progression was independently associated with faster deterioration of O...
We identify biomarkers for disease progression in three type 2 diabetes cohorts encompassing 2,973 i...
Aims/hypothesis Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) D...
Aims/hypothesis: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) ...
This is the author accepted manuscript. The final version is available from the American Diabetes As...
OBJECTIVEWe investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D).RE...
Objective: We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D)....
OBJECTIVE: We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D)....
Aim: Subclasses of different glycaemic disturbances could explain the variation in characteristics o...
Aims/hypothesisThe DIRECT (Diabetes Research on Patient Stratification) Study is part of a European ...
Aims/hypothesis: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a Europea...
We identify biomarkers for disease progression in three type 2 diabetes cohorts encompassing 2,973 i...
Aims/hypothesis Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) D...
Aims/hypothesis: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) ...
This is the author accepted manuscript. The final version is available from the American Diabetes As...
OBJECTIVEWe investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D).RE...
Objective: We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D)....
OBJECTIVE: We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D)....
Aim: Subclasses of different glycaemic disturbances could explain the variation in characteristics o...
Aims/hypothesisThe DIRECT (Diabetes Research on Patient Stratification) Study is part of a European ...
Aims/hypothesis: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a Europea...
We identify biomarkers for disease progression in three type 2 diabetes cohorts encompassing 2,973 i...
Aims/hypothesis Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) D...
Aims/hypothesis: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) ...